Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Taxes 3Paclitaxel 3Immunoglobulin G 3Disulfides 3Carboplatin 3Bevacizumab 3Gemcitabine 2adavosertib 1X-Rays 1Specimen Handling 1Platinum 1Metformin 1Mesenchymal Stem Cell Transplantation 1Magnetic Resonance Spectroscopy 1Drug Therapy 1Docetaxel 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brenner Tumor × adavosertib × 1 year × Clear all
NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
124 enrolled 17 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡